D&D Pharmatech Confident As It Takes On Parkinson’s, Alzheimer’s
Among Top Global Biotech Fundraisers Last Year
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.
